BrightSpring Health prescriptions filled in fiscal 2026
Short Answer
Both the model and the market expect BrightSpring Health prescriptions filled in fiscal 2026 to be Above 42.9 million, with no compelling evidence of mispricing.
1. Executive Verdict
- BrightSpring's FY2026 prescription volume will likely be below 42.9 million, following H1 2026 declines.
- H2 2026 volume is projected at 22.20 million scripts, based on updated revenue guidance.
- Medicare Part D changes, effective January 2026, may influence prescription demand.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 42.9 million | 0.0% | 0.0% | Research does not highlight strong supporting evidence. |
| Above 43.1 million | 0.0% | 0.0% | Research does not highlight strong supporting evidence. |
| Above 43.3 million | 0.0% | 0.0% | Research does not highlight strong supporting evidence. |
| Above 43.5 million | 0.0% | 0.0% | Research does not highlight strong supporting evidence. |
| Above 43.7 million | 0.0% | 0.0% | Research does not highlight strong supporting evidence. |
Current Context
BrightSpring raised 2026 guidance, driven by pharmacy performance and M&A. For full-year 2026, BrightSpring increased its guidance for continuing operations, excluding the Community Living business, to $15.1 billion–$15.425 billion in revenue and $820 million–$845 million in Adjusted EBITDA [^][^][^]. The company's pharmacy segment performance was evident with revenue per script of $314.20 and gross profit per script of $27.50 as of Q2 2026 [^][^]. Operational developments include the completion of the $835 million divestiture of the Community Living business on March 30 [^], and the integration of Amedisys and LHC Group assets, which are expected to add approximately $35 million in Adjusted EBITDA during 2026 [^][^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This market is highly illiquid, with zero contracts traded. The price chart shows a brief, anomalous spike to 48.0% on August 13 before the probability settled at its current level of 2.0%. With no volume, these price movements do not reflect actual trading activity or a consensus view. Instead, they likely represent the placement and subsequent removal or adjustment of a single participant's unfilled orders. The overall trend is flat and indicative of a dormant market with no meaningful price discovery taking place.
The market's low probability pricing is inconsistent with BrightSpring's reported performance data. The company filled 21.57 million prescriptions in the first half of 2026. This performance puts the full-year total on a pace to exceed 43.1 million, which is above the 42.9 million threshold for a "YES" resolution. The company also increased its full-year 2026 guidance, citing pharmacy performance. The brief spike to 48.0% may represent a fleeting acknowledgment of these fundamentals, but the lack of any traded volume prevented this view from being established in the market price.
Due to the complete absence of trading, there are no established support or resistance levels. The current 2.0% price implies very low market confidence in the "YES" outcome, but this reading is unreliable. The lack of volume suggests market sentiment is effectively undeveloped, with a significant disconnect between the company's publicly available performance data and the dormant price of this contract.
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
📈 August 13, 2026: 14.0pp spike
Price increased from 1.0% to 15.0%
Outcome: Above 43.1 million
What happened: The provided research indicates there is no evidence of a 14.0 percentage point spike in the BrightSpring Health prescriptions market on August 13, 2026 [^]. BrightSpring's Q2 2026 earnings, released on July 31, 2026, reported flat prescription volume for the first half of 2026 and a 1% decrease from H1 2025, despite raising overall revenue and EBITDA guidance [^]. Therefore, no primary driver for the stated price movement can be identified, as the movement itself is unconfirmed by the available information. Social media activity is irrelevant, as there's no evidence of a market spike for it to influence.
4. Market Data
Contract Snapshot
This market resolves to YES if BrightSpring Health fills above 43.7 million prescriptions in fiscal 2026, and to NO if they fill 43.7 million or fewer. Trading concludes on March 5, 4:00 PM EST, with payouts by June 3, 2027. No special settlement conditions are detailed in the provided text.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 42.9 million | $0.99 | $0.98 | 0% |
| Above 43.1 million | $0.99 | $0.85 | 0% |
| Above 43.3 million | $0.98 | $0.98 | 0% |
| Above 43.5 million | $0.98 | $0.98 | 0% |
| Above 43.7 million | $0.98 | $0.85 | 0% |
Market Discussion
BrightSpring Health Services dispensed 21,573,914 prescriptions in the first half of fiscal 2026, marking a 1% decrease compared to the prior year period, with 10,844,038 prescriptions specifically filled in Q2 2026 [^][^][^]. Despite these flat prescription volumes, Pharmacy Solutions revenue saw significant growth in Q2 2026 due to a rise in revenue and gross profit per prescription, prompting BrightSpring to raise its full-year 2026 financial guidance as of July 31, 2026 [^][^][^][^]. Investor discussions indicate a focus on pharmacy unit economics to offset volume trends, rather than specific full-year prescription volume targets for 2026 [^][^][^].
5. Trader Dashboard
A deterministic, per-market integrity scorecard computed from order-book and price data. Higher is better for Trader Trust, Liquidity, Move Quality and Resolution; higher means more risk for Quote Risk and Avoid Risk.
Above 42.9 millionPrimaryTrader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—
Move Quality—No significant move
- Factor
Above 43.1 millionTrader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—
Move Quality—No significant move
- Factor
Above 43.3 millionTrader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—
Move Quality—No significant move
- Factor
Above 43.5 millionTrader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—
Move Quality—No significant move
- Factor
Above 43.7 millionTrader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—
Move Quality—No significant move
- Factor
trader_dashboard_lean_v1.13 · computed Aug 13, 2026
6. What is the expected impact of integrating Amedisys and LHC Group assets on BrightSpring's prescription volume in the second half of fiscal 2026?
| Acquired Assets Revenue (Q2 2026) | Approximately $78 million [^][^][^] |
|---|---|
| Acquired Assets Adjusted EBITDA (Q2 2026) | Approximately $8 million [^][^][^] |
| Pharmacy Solutions Prescriptions (H1 2026) | 21,573,914 [^] |
The integration of Amedisys and LHC Group assets does not directly impact BrightSpring's prescription volume. There is no evidence indicating a direct effect on the prescription volume of BrightSpring's Pharmacy Solutions segment in the second half of fiscal 2026 [^][^][^]. The assets acquired from Amedisys and LHC Group are part of BrightSpring's Provider Services (home healthcare) segment, which operates distinctly from its Pharmacy Solutions business line [^][^][^].
Integrated assets boost Provider Services, while Pharmacy Solutions shows separate trends. In Q2 2026, the acquired Amedisys and LHC Group assets contributed approximately $78 million in revenue and $8 million in adjusted EBITDA [^][^][^]. For the full year 2026, the integration is projected to add approximately $35 million in adjusted EBITDA to BrightSpring, an increase from previous guidance [^][^][^]. The Pharmacy Solutions segment, however, is a separate entity whose recent growth is driven by its clinical and commercial teams, not the home health acquisitions [^][^][^]. In the first half of fiscal 2026, the Pharmacy Solutions segment dispensed 21,573,914 prescriptions, showing a 1% decline compared to the first half of 2025 [^].
7. How does BrightSpring's year-over-year prescription volume growth compare to that of its key competitor, Option Care Health, in H1 2026?
| BrightSpring H1 2026 Prescription Decline | 1% year-over-year [^] |
|---|---|
| BrightSpring H1 2026 Prescriptions Dispensed | 21,573,914 [^] |
| Option Care Health Q2 2026 Net Revenue Growth | 1.9% [^] |
BrightSpring's prescription volume declined slightly in H1 2026. BrightSpring Health's Pharmacy Solutions segment experienced a 1% year-over-year decline in prescriptions dispensed during H1 2026, totaling 21,573,914, down from 21,729,067 in H1 2025. Despite this minor volume reduction, the segment's pharmacy revenue grew significantly, driven by an increase in revenue per script [^].
Direct prescription volume comparison is not feasible with available data. Option Care Health does not use prescription volume as a primary key performance indicator; instead, it focuses on metrics such as patient census, net revenue, and adjusted EBITDA. For Q2 2026, Option Care Health reported a modest 1.9% net revenue growth, which was primarily influenced by service and therapy mix rather than script volume [^]. Consequently, a direct year-over-year comparison of prescription volume growth between BrightSpring Health and Option Care Health for H1 2026 cannot be made based on the provided data [^][^].
8. Based on BrightSpring's updated FY2026 revenue guidance, what is the implied prescription volume for H2 2026, considering the revenue per script reported in H1?
| Implied H2 2026 Prescription Volume | 22.20 million scripts [^][^] |
|---|---|
| FY2026 Pharmacy Revenue Guidance | $13,200 million to $13,500 million [^][^][^] |
| H1 2026 Average Revenue per Script | $304.93 [^][^] |
BrightSpring's H2 2026 prescription volume is projected at 22.20 million scripts. This projection for BrightSpring's Pharmacy segment in the second half of 2026, approximately 22.20 million scripts, considers the company's updated FY2026 revenue guidance [^][^]. The calculation assumes that the average revenue per script reported in H1 2026 will remain consistent for H2 2026 [^][^].
The projection uses FY2026 guidance and H1 2026 financial data. BrightSpring's full-year 2026 Pharmacy segment revenue guidance ranges from $13,200 million to $13,500 million [^][^][^]. In H1 2026, the Pharmacy segment recorded $6,579.5 million in revenue, with an average revenue per script of $304.93 [^][^]. Utilizing the midpoint of the FY2026 guidance, which is $13,350 million, the implied H2 2026 revenue calculates to approximately $6,770.5 million [^][^][^]. Consequently, based on these figures and the H1 average revenue per script, the estimated H2 2026 prescription volume is anticipated to range from approximately 21.71 million to 22.69 million scripts [^][^].
9. What is the scheduled release timeline for BrightSpring's Q3 and Q4 2026 financial reports, which will contain the official data needed to resolve this market?
| Estimated Q3 2026 Report Release | October 27, 2026, or October 29, 2026 [^][^] |
|---|---|
| Estimated Q4 and Full FY 2026 Report Release | Late February 2027 [^] |
| Financial Reporting Frequency | Quarterly with Forms 10-Q and 10-K [^][^] |
BrightSpring Health Services expects to release its Q3 2026 financial report around October 27 or October 29, 2026 [^] [^] . Following this, the company anticipates its Q4 2026 and full fiscal year 2026 financial results will be published in late February 2027 [^].
This projected timeline for BrightSpring's Q4 and full fiscal year 2026 results is consistent with the company's historical reporting practices. BrightSpring typically releases its full-year results in late February of the subsequent year, as demonstrated by the 2025 fiscal year results, which were issued on February 27, 2026 [^].
10. Are there any anticipated changes to Medicare or Medicaid reimbursement policies in late 2026 that could influence prescription demand for BrightSpring's services?
| Medicare Part D Changes Effective | January 1, 2026 [^][^] |
|---|---|
| BrightSpring IRA Headwinds | $45 million per remaining quarter in 2026 [^][^] |
| BrightSpring 2026 Prescription Volume | Essentially flat [^][^][^][^] |
Medicare Part D changes will significantly impact BrightSpring's pharmacy finances. Effective January 1, 2026, significant modifications to Medicare Part D, including negotiated drug prices and a $2,100 out-of-pocket spending cap, have altered pharmacy reimbursement structures [^][^]. These changes are projected to result in $45 million in IRA-related headwinds for BrightSpring’s Pharmacy Solutions segment for each remaining quarter in 2026 [^][^].
BrightSpring's volume remained flat amid new competitive landscape challenges. Throughout 2026, BrightSpring's pharmacy prescription volume saw essentially flat growth, with revenue increases primarily driven by per-prescription economics rather than higher volume [^][^][^][^]. Additionally, a government action in May 2026 imposed a moratorium, blocking new home healthcare and hospice providers from Medicare enrollment for at least six months [^]. While this action may influence the competitive environment for BrightSpring’s provider services in late 2026, the specific impact on prescription demand for BrightSpring's services, beyond its general effect on reimbursement and economic factors, remains undefined [^][^][^][^][^].
11. What Could Change the Odds
Key Catalysts
BrightSpring's updated full-year 2026 guidance, as of Q2, includes total revenue projections of $15.1 billion to $15.425 billion, pharmacy solutions revenue of $13.2 billion to $13.5 billion, and total adjusted EBITDA of $820 million to $845 million [^] . This outlook accounts for both potential upside and downside pressures.
Bullish catalysts for BrightSpring stem from growth in Specialty and Infusion pharmacy segments, successful integration of Amedisys and LHC assets, and operational efficiency gains [^] . Specifically, the company anticipates a $35M EBITDA boost from the integration of Amedisys and LHC Group assets [^].
Conversely, bearish risks include margin pressure from the Inflation Reduction Act, representing a $45M quarterly headwind, along with broader reimbursement exposure and potential challenges in integration execution [^] [^] [^] . For the remainder of 2026, key timeline factors involve finalizing the integration of acquired assets, achieving milestones in AI/automation adoption, and monitoring stabilization within the Home & Community Pharmacy segment [^][^].
Key Dates & Catalysts
- Expiration: June 03, 2027
- Closes: June 03, 2027
12. Decision-Flipping Events
- Trigger: BrightSpring's updated full-year 2026 guidance, as of Q2, includes total revenue projections of $15.1 billion to $15.425 billion, pharmacy solutions revenue of $13.2 billion to $13.5 billion, and total adjusted EBITDA of $820 million to $845 million [^] .
- Trigger: This outlook accounts for both potential upside and downside pressures.
- Trigger: Bullish catalysts for BrightSpring stem from growth in Specialty and Infusion pharmacy segments, successful integration of Amedisys and LHC assets, and operational efficiency gains [^] .
- Trigger: Specifically, the company anticipates a $35M EBITDA boost from the integration of Amedisys and LHC Group assets [^] .
14. Historical Resolutions
No historical resolution data available for this series.
